TN2015000395A1 - Respirable agglomerates of porous carrier particles and micronized drug - Google Patents

Respirable agglomerates of porous carrier particles and micronized drug

Info

Publication number
TN2015000395A1
TN2015000395A1 TN2015000395A TN2015000395A TN2015000395A1 TN 2015000395 A1 TN2015000395 A1 TN 2015000395A1 TN 2015000395 A TN2015000395 A TN 2015000395A TN 2015000395 A TN2015000395 A TN 2015000395A TN 2015000395 A1 TN2015000395 A1 TN 2015000395A1
Authority
TN
Tunisia
Prior art keywords
porous carrier
carrier particles
respirable agglomerates
micronized drug
active agent
Prior art date
Application number
TN2015000395A
Other languages
English (en)
Inventor
Michael Hartman
Thomas Tarara
Patrick Teung
Jeffry Weers
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2015000395A1 publication Critical patent/TN2015000395A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TN2015000395A 2013-03-14 2015-09-04 Respirable agglomerates of porous carrier particles and micronized drug TN2015000395A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784842P 2013-03-14 2013-03-14
PCT/IB2014/059739 WO2014141135A1 (en) 2013-03-14 2014-03-13 Respirable agglomerates of porous carrier particles and micronized drug

Publications (1)

Publication Number Publication Date
TN2015000395A1 true TN2015000395A1 (en) 2017-01-03

Family

ID=50478894

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2015000395A TN2015000395A1 (en) 2013-03-14 2015-09-04 Respirable agglomerates of porous carrier particles and micronized drug

Country Status (22)

Country Link
US (2) US9452139B2 (enExample)
EP (1) EP2968570A1 (enExample)
JP (1) JP6374414B2 (enExample)
KR (1) KR20150129716A (enExample)
CN (1) CN105188757B (enExample)
AU (2) AU2014229265A1 (enExample)
BR (1) BR112015021814A2 (enExample)
CA (1) CA2905615A1 (enExample)
CL (1) CL2015002632A1 (enExample)
EA (1) EA201591729A1 (enExample)
GT (1) GT201500295A (enExample)
HK (1) HK1212616A1 (enExample)
IL (1) IL240963A (enExample)
MA (1) MA38397A1 (enExample)
MX (1) MX2015012814A (enExample)
PE (1) PE20151655A1 (enExample)
PH (1) PH12015501882A1 (enExample)
SA (1) SA515361055B1 (enExample)
SG (1) SG11201506397QA (enExample)
TN (1) TN2015000395A1 (enExample)
WO (1) WO2014141135A1 (enExample)
ZA (1) ZA201505768B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CA2797118C (en) 2010-04-22 2021-03-30 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
SG11201505556VA (en) * 2013-01-31 2015-08-28 Prosonix Ltd Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy
US9452139B2 (en) * 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
CA2940599A1 (en) * 2014-03-27 2015-10-01 Novartis Ag Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients
RS62140B1 (sr) 2014-04-15 2021-08-31 Vertex Pharma Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
WO2016142708A2 (en) * 2015-03-10 2016-09-15 Cipla Limited Pharmaceutical composition
US10423736B2 (en) * 2015-08-28 2019-09-24 University Of British Columbia Methods and systems for simulating hydrodynamics in gas-solid fluidized beds
EP3335699A1 (en) * 2016-12-15 2018-06-20 H e x a l Aktiengesellschaft Selexipag formulation in liquisolid system
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
WO2019060595A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
US20200324064A1 (en) * 2019-04-10 2020-10-15 Cai Gu Huang Inhalation Device for Administering Powdered Pharmaceutical Composition
US20200375945A1 (en) * 2019-06-03 2020-12-03 Cai Gu Huang Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
MX2022001884A (es) * 2019-08-15 2022-03-11 Abbott Lab Proceso de fabricacion de polvo nutricional usando micronizacion y composicion en polvo.
IL297251A (en) * 2020-04-13 2022-12-01 Univ Basel lsd dose detection
CN114344285B (zh) * 2020-10-14 2023-11-14 江苏恒瑞医药股份有限公司 改良的可吸入团聚物
WO2022122012A1 (zh) * 2020-12-11 2022-06-16 江苏恒瑞医药股份有限公司 用于肺部递送的药物组合物
CN113318097A (zh) * 2021-04-29 2021-08-31 珠海瑞思普利医药科技有限公司 一种抗特发性肺纤维化的粉雾剂及制备方法
CN116785246A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 一种药物微球及含其的气雾剂
CN116785239A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 喷雾冷冻干燥制备微球的方法
CN117357485B (zh) * 2023-11-01 2024-09-24 山东京卫制药有限公司 一种改良的可吸入的载体颗粒及应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
EP0057401B1 (en) 1981-02-02 1984-08-01 Schering Corporation Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
NZ243314A (en) 1991-06-26 1994-07-26 Schering Corp Powder dispenser; single metered dose rotated to dispensing conduit
RU2111020C1 (ru) 1992-12-18 1998-05-20 Шеринг Корпорейшн Ингалятор для порошковых лекарств
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
CN1318104C (zh) 1994-09-21 2007-05-30 耐科塔医药公司 送料管组件
ATE209053T1 (de) 1996-01-03 2001-12-15 Glaxo Group Ltd Inhaliervorrichtung
ES2172763T3 (es) 1996-02-21 2002-10-01 Schering Corp Inhalador de medicamento en polvo.
EP1369414A1 (de) 1996-11-11 2003-12-10 Christian R. Noe Enantiomerenreine Arylcycloalkyl-Hydroxycarbonsäureester, Verfahren zu ihrer Herstellung und ihre Verwendung als Muskarinrezeptor-Modulatoren
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
UA73924C2 (en) 1998-10-09 2005-10-17 Nektar Therapeutics Device for delivering active agent formulation to lungs of human patient
US20070212422A1 (en) 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
RU2221552C2 (ru) 1998-11-13 2004-01-20 Джаго Рисерч Аг Сухой порошок для ингаляции
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
ATE422924T1 (de) 1999-05-28 2009-03-15 Nektar Therapeutics Gerät zum abgeben von abgemessenen mengen von medikamente beinhaltendem aerosol
US6679256B2 (en) 1999-12-17 2004-01-20 Nektar Therapeutics Systems and methods for extracting powders from receptacles
US7069929B2 (en) 2000-02-01 2006-07-04 Quadrant Technologies Limited Dry powder inhaler
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
AU2003287132B2 (en) 2002-12-13 2009-03-12 Adagit Pharmaceutical porous particles
ES2383367T5 (es) 2003-04-09 2021-03-31 Novartis Ag Aparato de pulverización en forma de aerosol con protección de entrada de aire
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
GB2407042B (en) 2003-10-17 2007-10-24 Vectura Ltd Inhaler
JP4708369B2 (ja) 2004-02-24 2011-06-22 マイクロドース セラピューテクス，インコーポレイテッド 合成ジェットに基づく薬剤投与装置
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
BRPI0713951B8 (pt) 2006-06-30 2021-05-25 Novartis Ag derivados de quinazolina, e composição farmacêutica
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
ES2596263T3 (es) 2006-10-25 2017-01-05 Novartis Ag Aparato de dispersión de polvo
CA2724009C (en) 2008-05-15 2016-10-11 Novartis Ag Pulmonary delivery of a fluoroquinolone
US20120022127A1 (en) 2009-04-09 2012-01-26 Thomas Allmendinger Process for preparing pyrrolidinium salts
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
SG184352A1 (en) 2010-04-01 2012-10-30 Chiesi Farma Spa Process for preparing carrier particles for dry powders for inhalation
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9452139B2 (en) * 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug

Also Published As

Publication number Publication date
ZA201505768B (en) 2017-03-29
KR20150129716A (ko) 2015-11-20
MA38397A1 (fr) 2018-01-31
SG11201506397QA (en) 2015-09-29
BR112015021814A2 (pt) 2017-07-18
JP6374414B2 (ja) 2018-08-15
GT201500295A (es) 2017-09-28
JP2016512494A (ja) 2016-04-28
AU2014229265A1 (en) 2015-09-03
SA515361055B1 (ar) 2016-11-13
WO2014141135A1 (en) 2014-09-18
US9744178B2 (en) 2017-08-29
US9452139B2 (en) 2016-09-27
PH12015501882A1 (en) 2015-12-07
IL240963A (en) 2017-05-29
EP2968570A1 (en) 2016-01-20
CN105188757B (zh) 2019-04-30
CA2905615A1 (en) 2014-09-18
CL2015002632A1 (es) 2016-03-28
US20140302147A1 (en) 2014-10-09
AU2017203258B2 (en) 2019-06-20
PE20151655A1 (es) 2015-11-26
HK1212616A1 (zh) 2016-06-17
EA201591729A1 (ru) 2016-05-31
MX2015012814A (es) 2016-02-03
US20160354388A1 (en) 2016-12-08
IL240963A0 (en) 2015-11-30
AU2017203258A1 (en) 2017-06-08
CN105188757A (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
TN2015000395A1 (en) Respirable agglomerates of porous carrier particles and micronized drug
PH12013500235A1 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
PH12016500043A1 (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-andrenergic for administration by inhalation
MY184654A (en) Novel dosage form and formulation of abediterol
PH12014502746B1 (en) Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
EA201491281A1 (ru) КОМПОЗИЦИЯ В ФОРМЕ СУХОГО ПОРОШКА, СОДЕРЖАЩАЯ КОРТИКОСТЕРОИД И β-АДРЕНЕРГИЧЕСКОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, ДЛЯ ВВЕДЕНИЯ ИНГАЛЯЦИЕЙ
MX2015012529A (es) Deamorfizacion de formulaciones secadas por pulverizacion a traves de pulverizacion de la mezcla.
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
MX2018003271A (es) Formulaciones de nicotina y metodos para producir y utilizar las mismas.
MY191712A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
PH12014502619A1 (en) Novel dosage and formulation
MX2018015969A (es) Formulaciones tensoactivas para inhalacion.
MX2015015150A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
MX375187B (es) Composiciones farmacéuticas secas que comprenden nanopartículas de agente activo ligadas a partículas portadoras.
EA033247B1 (ru) Способ получения сухих порошковых композиций для ингаляций
MX2017004633A (es) Formulaciones que contienen tiotropio, aminoacidos y acidos, y metodos de estas.
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
MY191295A (en) Pharmaceutical composition containing budesonide and formoterol
TN2013000015A1 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
TH159392A (th) สูตรผสมผงแห้งที่ประกอบรวมด้วยแอนติโคลิเนอร์จิก, คอร์ติโคสเตียรอยด์ และเบตา-แอดรีเนอร์จิกสำหรับการให้โดยการสูด
TH100973B (th) วิธีการเตรียมองค์ประกอบผงแห้งสำหรับสูดดม